普罗帕酮治疗严重室性心律失常。
Propafenone for the treatment of severe ventricular arrhythmias.
作者信息
Rabkin S W, Rotem C E, Boroomand-Rashti K, Bar-Shlomo B
出版信息
Can Med Assoc J. 1984 Sep 15;131(6):601-3.
Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone. This therapy was associated with complete or nearly complete suppression of premature ventricular beats in 15 (71%) of the patients, satisfactory control in 4 (19%) and no control in 2 (10%). The majority reported no adverse effects. The most frequent complaints were nausea or epigastric discomfort (in five patients) and lightheadedness or dizziness (in three patients). Thus, propafenone appeared to be an effective antiarrhythmic agent with an acceptable frequency of side effects when administered to patients whose ventricular arrhythmias were difficult to treat.
21例严重室性心律失常患者，使用目前其他抗心律失常药物无法控制，或对这些药物不耐受，接受了一种新型抗心律失常药物普罗帕酮的治疗。该治疗使15例（71%）患者的室性早搏得到完全或几乎完全抑制，4例（19%）患者控制良好，2例（10%）患者未得到控制。大多数患者报告无不良反应。最常见的主诉是恶心或上腹部不适（5例患者）以及头晕（3例患者）。因此，对于室性心律失常难以治疗的患者，普罗帕酮似乎是一种有效的抗心律失常药物，且副作用发生率可接受。
Zotero 插件